Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (20)

2023

  1. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

    Frontiers in Immunology, Vol. 13

  2. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

    Frontiers in Immunology

  3. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma

    Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65

  4. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

  5. Silver nanoparticles induce a non-immunogenic tumor cell death

    Journal of Immunotoxicology, Vol. 20, Núm. 1

  6. Targeting FOXP3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental Breast Cancer

    Viruses, Vol. 15, Núm. 9

2022

  1. Impact of tumor microenvironment on adoptive T cell transfer activity

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 1-31

  2. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

  3. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Cellular cytotoxicity is a form of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. Long-term systemic expression of a novel pd-1 blocking nanobody from an aav vector provides antitumor activity without toxicity

    Biomedicines, Vol. 8, Núm. 12, pp. 1-19

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  2. Today's special on the anticancer menu: Immunomodulation by antifolates

    Clinical Cancer Research, Vol. 25, Núm. 23, pp. 6890-6892

  3. Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-a

    Journal of Immunology, Vol. 203, Núm. 3, pp. 696-704

2018

  1. The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

    OncoImmunology, Vol. 7, Núm. 4

2017

  1. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy

    Cancer Research, Vol. 77, Núm. 13, pp. 3672-3684

2015

  1. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage

    Oncotarget, Vol. 6, Núm. 29, pp. 27160-27175

  2. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189